Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adagene

1.78
-0.1400-7.29%
Post-market: 1.77-0.0100-0.56%19:58 EDT
Volume:92.56K
Turnover:171.80K
Market Cap:83.89M
PE:-2.77
High:1.93
Open:1.89
Low:1.76
Close:1.92
52wk High:3.16
52wk Low:1.33
Shares:47.13M
Float Shares:12.73M
Volume Ratio:2.74
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6428
EPS(LYR):-0.7423
ROE:-63.26%
ROA:-24.89%
PB:2.21
PE(LYR):-2.40

Loading ...

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

GlobeNewswire
·
Oct 31

Adagene’s Innovative Cancer Study: A Potential Game-Changer in Oncology

TIPRANKS
·
Oct 28

Adagene Initiated at Buy by LUCID CAPITAL MARKETS

Dow Jones
·
Sep 18

Adagene initiated with a Buy at Lucid Capital

TIPRANKS
·
Sep 18

Adagene expands SAFEbody collaboration, license agreement with Exelixis

TIPRANKS
·
Sep 16

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

GlobeNewswire
·
Sep 16

Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Reuters
·
Sep 05

Press Release: Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Dow Jones
·
Sep 03

Adagene Inc. to Participate in Investor Conferences in New York

Reuters
·
Aug 26

Adagene Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 15

Adagene H1 Adj. EPS $(0.19) Beats $(0.34) Estimate

Benzinga
·
Aug 13

Adagene Inc. Reports Reduced Net Loss of $13.5M for H1 2025, Down from $17.0M in H1 2024; R&D Expenses Decrease by 18%

Reuters
·
Aug 13

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

GlobeNewswire
·
Aug 13

Leerink Partners Initiates Adagene at Outperform With $7 Price Target

MT Newswires Live
·
Aug 06

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

GlobeNewswire
·
Jul 15

Adagene Inc. Partners with ConjugateBio to Develop Novel Antibody Drug Conjugates

Reuters
·
Jul 08

BRIEF-Adagene Announces Up To $25 Million Strategic Investment From Sanofi

Reuters
·
Jul 01

Adagene Inc. Announces New Clinical Trial for Muzastotug in Advanced Solid Tumors Following $25 Million Strategic Investment by Sanofi

Reuters
·
Jul 01